Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 7/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17049270 | 0.81 | OPRM1 (0.56) | NPSR1GPR55OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL2961620 | 0.81 | NPSR1 (0.50) | NPSR1GPR55OPRM1OPRD1OPRK1 | |
| SCHEMBL10047375 | 0.80 | NPSR1 (0.61) | NPSR1GPR55OPRM1OPRD1OPRK1 | |
| SCHEMBL27272480 | 0.78 | CYP3A4 (0.54) | NPSR1GPR55OPRD1CYP2D6CYP3A4 | |
| SCHEMBL75705 | 0.78 | CYP3A4 (0.54) | NPSR1GPR55OPRM1OPRD1OPRK1 | |
| SCHEMBL70986 | 0.77 | OPRM1 (0.49) | NPSR1GPR55OPRM1OPRD1OPRK1 | |
| SCHEMBL31741187 | 0.77 | NPSR1 (0.47) | NPSR1GPR55OPRM1OPRD1OPRK1 | |
| SCHEMBL71724 | 0.77 | NPSR1 (0.57) | NPSR1GPR55OPRM1OPRD1OPRK1 | |
| SCHEMBL15797515 | 0.77 | NPSR1 (0.57) | NPSR1GPR55OPRM1OPRD1OPRK1 | |
| SCHEMBL9359082 | 0.77 | NPSR1 (0.57) | NPSR1GPR55OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1961750-B1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO CO LTD (JP) | 2013-09-18 | — | — | EP | disclosed |
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1961750-A1 | VLA-4 INHIBITORY DRUG | Daiichi Sankyo Company, Limited (JP) | 2008-08-27 | — | — | EP | disclosed |
| WO-2008095912-A2 | ENANTIOPURE PHARMACOLOGICALLY ACTIVE TRICYCLIC BENZIMIDAZOLES | NYCOMED GMBH (DE) | 2008-08-14 | — | — | WO | disclosed |
| EP-0788498-B1 | PHENYLOXAZOLIDINONE ANTIMICROBIALS | UPJOHN CO (US) | 2001-08-16 | — | — | EP | disclosed |
| US-5883093-A | TREATING MICROBIAL INFECTIONS IN WARM BLOODED ANIMALS, INCLUDING HUMANS | PHARMACIA & UPJOHN COMPANY (US) | 1999-03-16 | — | — | US | disclosed |
| EP-0788498-A1 | PHENYLOXAZOLIDINONE ANTIMICROBIALS | PHARMACIA & UPJOHN COMPANY (US) | 1997-08-13 | — | — | EP | disclosed |
| WO-1996013502-A1 | PHENYLOXAZOLIDINONE ANTIMICROBIALS | PHARMACIA & UPJOHN COMPANY (US) | 1996-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | NPSR1 1592/4885GPR55 2104/4885OPRM1 383/4885 |
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | NPSR1 1517/4885GPR55 2124/4885OPRM1 376/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | NPSR1 2018/4885GPR55 2946/4885OPRM1 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.